Compare Transocean Ltd (RIG) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs 10X Genomics Inc — how do they compare? Transocean Ltd trades at $5.55 (market cap $6.19B), while 10X Genomics Inc trades at $81.4 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Transocean Ltd for 18 Days and 10X Genomics Inc for 92 Days on average.
| RIG | TXG | |
|---|---|---|
Market Cap | $6.19B | $10.07B |
Volume | 30,564,415 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $7.58 | $97.74 |
52-Week Low | $3.08 | $11.48 |
Typical Hold Time | 18 Days | 92 Days |
Enterprise Value | $10.80B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.595, up 3.8% with bullish technical signals despite mixed earnings. The company shows strong revenue growth to $4.1B in 2026 but remains unprofitable with a -40.24% net margin. Recent $80M and $300M contract wins boost backlog, while the $5.8B Valaris acquisition advances after DOJ approval. Cash flow improved with $995M operating cash in 2026, supporting deleveraging efforts amid high debt levels.
RIG offers speculative upside through offshore cycle leverage and contract growth, but high debt and persistent losses pose significant risks. Analyst consensus is divided with 39% buy ratings, reflecting optimism about cash flow improvement versus concerns over profitability and execution risks from major acquisitions.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
